AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Catherine J. Reynolds et al.

Summary: Vaccination with a single dose of BNT162b2 after prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. In contrast, individuals without prior infection showed reduced immunity against variants after receiving a single vaccine dose.

SCIENCE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC

Related references

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Export Citation

Share Paper